Compounders Research Compare

Kura Oncology, Inc.(KURA)

Biotechnology · San Diego, CA

$10.54-0.08 (-0.75%)

Delayed quote: Oct 6, 2026, 10:05 AM EDT

About Kura Oncology, Inc.

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.

San Diego, CA

260 employees

kuraoncology.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Troy Wilson

View full financials

EV/EBITDA Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBITDA ratio is N/A as of 2026-10-06T14:07:14.291Z.

Stored calculation inputs

Calculation as of: 2026-10-06T14:07:14.291Z.

Quote observation: 2026-10-06T14:05:17.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 935,681,807
Total debt · period ending 2026-06-30: 24,455,000
Cash · period ending 2026-06-30: 70,242,000
TTM operating EBITDA · period ending 2026-06-30: -314,803,000

FMP input reference: 19f1946388931e4ee5326c5171249fc23a65b0c9e42408d49e268755c1a57655

EV/Sales|P/E Ratio|EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

KURA EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

N/A

KURA Competitors' EV/EBITDA Ratio

Kura Oncology, Inc.

Current

Market Cap

$935.68M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CeriBell, Inc.

Market Cap

$935.25M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MoonLake Immunotherapeutics

Market Cap

$938.73M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

HealthStream, Inc.

Market Cap

$913.56M

EV/EBITDA Ratio

12.53x

TTM Avg

10.56x

3Y Avg

12.81x

5Y Avg

13.69x

Bioventus Inc.

Market Cap

$905.78M

EV/EBITDA Ratio

10.65x

TTM Avg

9.34x

3Y Avg

18.56x

5Y Avg

25.76x

Aktis Oncology, Inc.

Market Cap

$971.43M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Arbutus Biopharma Corp

Market Cap

$882.01M

EV/EBITDA Ratio

5.88x

TTM Avg

5.93x

3Y Avg

5.93x

5Y Avg

5.93x

LB Pharmaceuticals Inc Common Stock

Market Cap

$986.19M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Corvus Pharmaceuticals, Inc.

Market Cap

$868.65M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Latigo Biotherapeutics Inc.

Market Cap

$999.08M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
Kura Oncology, Inc. (KURA)	$935.68M	N/A	N/A	N/A	N/A
CeriBell, Inc. (CBLL)vs ›	$935.25M	N/A	N/A	N/A	N/A
MoonLake Immunotherapeutics (MLTX)vs ›	$938.73M	N/A	N/A	N/A	N/A
HealthStream, Inc. (HSTM)vs ›	$913.56M	12.53x	10.56x	12.81x	13.69x
Bioventus Inc. (BVS)vs ›	$905.78M	10.65x	9.34x	18.56x	25.76x
Aktis Oncology, Inc. (AKTS)vs ›	$971.43M	N/A	N/A	N/A	N/A
Arbutus Biopharma Corp (ABUS)vs ›	$882.01M	5.88x	5.93x	5.93x	5.93x
LB Pharmaceuticals Inc Common Stock (LBRX)vs ›	$986.19M	N/A	N/A	N/A	N/A
Corvus Pharmaceuticals, Inc. (CRVS)vs ›	$868.65M	N/A	N/A	N/A	N/A
Latigo Biotherapeutics Inc. (LTGO)vs ›	$999.08M	N/A	N/A	N/A	N/A

EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/Sales P/E Ratio EBITDA All Metrics